Vectura, the pharma company specialising in treatments for respiratory diseases, says a trial of one of its development drugs has shown better results than the main competitor.
The not-catchily titled QVA149 is a treatment delivered through an inhaler, mainly targeted at chronic obstructive pulmonary disease - a condition often seen in smokers, or people working in a polluted environment, which can cause debilitating bouts of breathlessness.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
-
Carers retire with an average pension of just £6,750A growing pensions gap shows carers retire with significantly less private pension income than the national average
-
8 of the best properties for sale with award-winning gardensThe best properties for sale with award-winning gardens – from a Victorian Gothic rectory in Hampshire, to a Georgian house in Kent with gardens designed by multiple Royal Chelsea Flower Show gold medallist Roger Platts
